|Polymer Microarrays for Biomaterial Development|
Simmonte, M.J.1, Dhaliwal, K.2, Cuschieri, K.3, Graham, S.V.4, Bradley, M.1
The application of polymer microarrays in the discovery of biocompatible and bioactive substrates. Progress towards biomaterial development for the treatment of SIRS (systemic inflammatory response syndrome), and improving cervical cytology.
|Knockdown of long noncoding RNAs in breast cancer |
1 Jennii Luu, 2 Jesper Maag, 1 Yanny Handoko, 3 Richard Redvers, 3,4 Robin L. Anderson, 5 Maren M. Gross , 2 Marcel E. Dinger, and 1,3 Kaylene J. Simpson 1 Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre; 2 Genome Informatics, The Kinghorn Cancer Centre, The Garvan Institute of Medical Research; 3 Metastasis Research Laboratory, Peter MacCallum Cancer Centre, 4 Sir Peter MacCallum Department of Oncology, University of Melbourne;
RNAi global collaboration study using Lincode siRNA in a primary screen of tumor and nontumor breast cell lines. Hundreds of lncRNAs are found to affect viability and cell morphology of breast cancer. Presented at Keystone Symposia on Long Noncoding RNAs: From Evolution to Function, Mar 15 - Mar 20, 2015.
|DETERMINATION OF THE QUALITY OF ACTIVE INGREDIENTS IN PAIN KILLERS USING GC-MS|
Elizabeth N.M Murago1, Nathan Oyaro1, Anthony N. Gachanja, Onditi O. Anam, Felix M. Mawili, Steve Lancaster
From this study, the pain killers sampled were found to have large error bars suggesting that there exist counterfeit drugs in the market. The brands mostly affected for analysis of acetaminophen were panadol, action, P500, P5500, elymol and neladol. The error bars for caffeine analysis were quite low indicating that all tablets either counterfeit or original maintained the same amount of this active ingredient.
|Human iPSC-derived hepatocytes and cardiomyocytes for drug toxicity testing|
AnnandRR; Vardaro R; Hamilton B; Akakira R; Tamura K; Yoshida S; Lin YC; Toyoda D; Kogami H; Okuda Y; Watanabe T; Inamura M
Human iPS-derived hepatocytes (ReproHepato™) and cardiomyocytes (ReproCardio 2™) are useful for in vitro toxicity assays.
|Using Cresset to grow and link distant fragment hits with sensible chemistry |
M J Slater; T Cheeseright
We describe a further extension to our fragment growing methodology to aid fragment optimisation through linking fragments that have been shown to bind to distinct (distant or adjacent) pockets.
|Improved Small RNA Library Preparation Workflow for Next-Generation Sequencing|
Sabrina Shore, Jordana Henderson, Anton McCaffrey, Gerald Zon, Richard Hogrefe
We describe an optimized small RNA NGS library prep workflow using chemically modified adapters which suppresses adapter dimers, allows for RNA inputs down to 1 ng and eliminates the need for a gel purification step, thus allowing full automation not previously possible.
|Flexible automated platform for blood group genotyping on DNA microarrays|
S. Paris1, D. Rigal1, V. Barlet1, M. Verdier1, N. Coudurier2, P. Bailly3, J.-C. Brès1,4
The purpose of this project was to set up and validate a flexible robotic platform using 96-well DNA microarray for multiplex blood group genotyping.
|Specificity of highly potent miRNA inhibitors|
Barbara Robertson, Andrew Dalby, Yuriy Fedorov, Jon Karpilow, Anastasia Khvorova1, Devin Leake, Annaleen Vermeulen
miRNA inhibitors are invaluable tools for elucidating the roles of miRNAs. However, potent inhibitors may also affect other miRNAs. To understand the potential cross-reactivity of miRNA inhibitors, various miRNA inhibitor designs were systematically tested. We demonstrate that mismatches both within and outside the seed region of the miRNA interfere with inhibition. Our findings indicate that features important for natural miRNA target recognition are also important for inhibitor specificity.
|Alternative miRNA design for therapeutic RNAi applications|
Anja van Brabant Smith, Barb Robertson, Annaleen Vermeulen, Christina Yamada, Angela Reynolds, Anastasia Khvorova, Devin Leake
For in vivo applications, the design of miRNA inhibitors and miRNA mimics must be optimized for stability and potency. However, stabilized miRNA mimic molecules can lose functionality compared to standard miRNA mimic molecules due, in part, to the activity of the stabilized passenger strand acting as a miRNA inhibitor. We discuss how mismatches affect the activity of the stabilized miRNA mimics, perhaps by generating a passenger strand that is less functional as an inhibitor molecule.